Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Current Deferred Revenue (2022 - 2025)

Bioregenx has reported Current Deferred Revenue over the past 4 years, most recently at $60227.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 69.43% year-over-year to $60227.0; the TTM value through Dec 2025 reached $60227.0, down 69.43%, while the annual FY2025 figure was $60227.0, 69.43% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $60227.0 at Bioregenx, down from $95775.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $629000.0 in Q4 2022 and troughed at $60227.0 in Q4 2025.
  • A 4-year average of $234690.9 and a median of $192610.0 in 2024 define the central range for Current Deferred Revenue.
  • On a YoY basis, Current Deferred Revenue climbed as much as 36.12% in 2025 and fell as far as 69.43% in 2025.
  • Year by year, Current Deferred Revenue stood at $629000.0 in 2022, then tumbled by 43.72% to $354000.0 in 2023, then tumbled by 44.35% to $197000.0 in 2024, then plummeted by 69.43% to $60227.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for BRGX at $60227.0 in Q4 2025, $95775.0 in Q3 2025, and $125174.0 in Q2 2025.